Beschreibung
The field of kidney cancer has dramatically evolved over the past several years due to notable advances. Most importantly, systemic treatment options have expanded to include combination regimens for advanced disease and expansion of treatment options in the adjuvant setting. Additionally, surgical management has evolved towards nephron-sparing and minimally invasive approaches for treatment of localized disease; the role of surgery and focal therapy are changing for patients with advanced disease. While kidney cancer is a common malignancy in both men and women worldwide, mortality has improved over time given advancements in modern oncology. This book provides a comprehensive, state-of-the art review of the field, and serves as a valuable resource for clinicians, surgeons and researchers with an interest in kidney cancer. The book reviews new data about systemic treatment options for patients with advanced disease including strategies in the treatment naïve and post frontline setting. It covers new data regarding perioperative and adjuvant treatments for patients with localized disease and will highlight novel targets and treatments under development. Integration of surgery and systemic therapy through cytoreductive and consolidative approaches has yielded provocative data that promises to further advance the field, and major advances in this domain will also be discussed. Additionally, the book discusses the evolving role of alternative focal approaches including radiation therapy for patients with advanced disease. This text serves as a very useful resource for physicians and researchers dealing with and interested in this challenging malignancy. Specifically, urologists, medical oncologists, radiation oncologists, basic science and translational researchers with interest in RCC, fellows in urologic oncology, upper level residents training in urology and medical oncology, and pharmaceutical partners interested in RCCwill benefit most significantly. Integrating Multidisciplinary Treatment for Advanced Renal Cell Carcinoma will provide a concise yet comprehensive summary of strategies for sequencing therapies that will help guide patient care and stimulate investigative efforts.
Autorenporträt
Rana R. McKay, MDAssociate Professor of Medicine and UrologyAssociate Director, Translational SciencesCo-Lead, Genitourinary Oncology Program Moores Cancer Center University of California San Diego3855 Health Sciences Drive La Jolla, CA 92037USA Eric A. Singer, MD, MA, MS, FACS, FASCO The Dave Longaberger Endowed Chair in Urology Professor of Urology and Bioethics Chief, Division of Urologic Oncology Director, Urologic Oncology Fellowship The Ohio State University Comprehensive Cancer Center 915 Olentangy River Road, Suite 3100, Columbus, OH, 43212 USA
Herstellerkennzeichnung:
Springer Verlag GmbH
Tiergartenstr. 17
69121 Heidelberg
DE
E-Mail: juergen.hartmann@springer.com
